It is believed that the pharmaceutical industry is the backbone of the country: it helps to ensure the health of its citizens. As of 2012 there were 19 licensed pharmaceutical manufacturers in Saudi Arabia.The list of the top pharmaceutical companies does not list foreign companies.
Foreign companies included, according to a research note by Aljazira Capital, in 2008 the following pharmaceutical companies had the largest market share in Saudi Arabia: GSK 10.3%, SPIMANCO 9.4%, Pfizer 6.4%, Tabuk 3.9%, Novartis 3.3%, Jamjoom 3.2%, Astra 3.1%, Julphar 3.1%, MSD 2.5% and Janssen 2.5%. As the largest economy in the GCC, by both population and GDP, Saudi Arabia also has the region’s largest pharmaceuticals market. The SFDA also wishes to ensure the tighter regulation of sales in order to enable accurate market analysis and a closer match between supply and demand, which would thereby cut wastage costs.Register now and also receive a complimentary 2-month licence to the OBG Research Terminal.Indeed, the NTP outlines a series of key performance indicators (KPIs) that each ministry and government agency will have to achieve by 2020. While the top pharmaceutical distribution companies are Tamer Group followed by SITCO Pharma in production the largest pharmaceutical companies are SPIMANCO, followed by Tabuk Pharmaceuticals and Jamjoom.
Saudi Arabia is in the heart of the Islamic world, besides, leveraging on Saudi Arabia’s geographical position, and the support of Saudi Export Development Authority and EXIM bank program, Saudi Arabia can boost the pharma exports to MENA region and to the rest of the world. Saudi Arabia Pharmaceutical Market to Reach US$ 5.2 Bn in 2016 Due to Rising Demand for Branded Drugs Saudi Arabia Pharmaceutical Market to expand at a …
Pharmaceuticals is largely immune from such trends, as Saudis continue to seek treatments for illnesses regardless of economic conditions.
You can also purchase a website subscription giving you unlimited access to all of our Reports online for 12 months.However, efforts by the government to curb pharmaceuticals expenditure and promote local production has resulted in generics becoming a fast-growing product.
This figure breaks down into $4.1bn spent on patented drugs, $2.3bn spent on generic drugs, and $1bn on over-the-counter medicines.
Marcopolis.net has ranked the largest pharmaceutical companies Saudi Arabia. The value of generics has risen by 3% in Saudi Arabia, even while being hit by an oil crisis. This system was still under construction in May 2017, with the SFDA expecting it to be completed by the end of the year.Growth has slowed down for many large multinational companies in recent years, while local and regional companies have gained market share. Market share of regional companies in the kingdom increased by 7% in five years – a positive result of the government’s policy of promoting domestic manufacturing.As the largest economy in the GCC, by both population and GDP, Saudi Arabia also has the region’s largest pharmaceuticals market.
is the leading corporation with 11.6% market share and The market is divided into the drug producing companies and pharmaceutical distribution companies. First, there is organic growth – the population has grown from just 9.9m in 1980 and 16.4m in 1990 to 32.6m in 2016, according to the General Authority for Statistics. It also gives the Kingdom a per capita drug spend some 113% higher than the global average.The market is set to be worth around $9.3bn by 2021, according to the Ministry of Health (MoH), representing cumulative pharmaceuticals expenditure of $42bn during 2017-21.
GDP per capita was around $16,698 in 1980, rising to $18,753 by 2010 and $20,481 in 2015. 1. over last MAT. “There was only one college of pharmacy 17 years ago. Oral Care in Saudi Arabia.
Saudi Arabia pharmaceutical market is dominated by branded drugs of various multinational companies, which are sold under second brand name in alliance with local companies and distributors.
The central objective of the SFDA is to secure complete control over the medicine supply chain in the country.
The plant has the capacity to manufacture 1bn tablets, 300m capsules and 30m bottles of suspensions and syrups per year. As of 2012 the sector comprised 27 companies 2012, taking around 18% of the market’s value between them.Find our research on the Bloomberg Terminal, Dow Jones Factiva, Eikon, S&P Capital IQ, LexisNexis and more.The SFDA is currently working on upgrading its e-infrastructure, to make it easier for importers, manufacturers and distributors to register, and is also attempting to integrate more closely with other government departments.